Navigation Links
Short-Term Drug Combo May Help Prevent Colon Cancer
Date:3/29/2010

Lab research finds only precancerous tissue affected, but more study needed

MONDAY, March 29 (HealthDay News) -- A two-drug combination that kills precancerous colon polyps without harming normal tissue offers a potential new way to prevent colon cancer, researchers say.

The combination of vitamin A acetate (RAc) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was effective in mice and in human colon cancer tissue in the lab, according to the results of a study published online March 28 in the journal Nature.

The treatment appears to solve a problem with current chemopreventive drugs, which is that they must be taken continuously and long term to be effective, thus exposing patients to possible side effects, said study senior author Xiangwei Wu, an associate professor in the head and neck surgery department at the University of Texas M.D. Anderson Cancer Center.

"This combination can be given short term and periodically to provide a long-term effect, which would be a new approach to chemoprevention," Wu said in a university news release.

However, further research is needed before this combination treatment can be considered for human clinical trials, Wu said.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about colon polyps.



-- Robert Preidt



SOURCE: University of Texas M.D. Anderson Cancer Center, news release, March 28, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Los Angeles Jewish Home Adds Short-Term Rehabilitative Care to Family of Services
2. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
3. Short-term radiation therapy successful on breast cancer
4. SNM calls Congress passage of fix for sustainable growth rate a short-term solution
5. Drug Combo Blocks HIV Infection in Mice
6. Combo PET-CT Scans Can Spot Hidden Cancers
7. Blood Thinner Combos Risky for Heart Attack Patients
8. OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent
9. Preventive Mastectomy May Not Lower Risks
10. Targeting cell pathway may prevent relapse of leukemia
11. Octreotide acetate does not prevent treatment-induced diarrhea in anorectal cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
Breaking Medicine Technology: